Application of Carbon Nanotubes in Drug Delivery of Non-Cancerous Diseases: A Review

2020 ◽  
Vol 26 ◽  
Author(s):  
Shahebaaz Khan ◽  
Puja Jawlikar ◽  
Swaroop Lahoti ◽  
Omprakash Bhusnure ◽  
Sohan Chitlange ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Alzheimer’S Disease ◽  
Carbon Nanotubes ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Pulmonary Diseases ◽  
Cancer Disease ◽  
The Past ◽  
The Future ◽  
Asthma Patients

: Carbon nanotubes (CNT) are the allotropes of carbon in nanosize rendering them popular in the field of medicines. These nano-based technologies are gaining interest in the treatment of disease which was previously seemed to be impossible for treating. CNT gained significance in the treatment of the majority of disorders such as Malaria, Alzheimer’s disease, Infectious disease, Asthma. Patients responsiveness has increased in cardiovascular, pulmonary diseases. To date, the number of reviews available in the literature covering applications of CNT in the cancer disease. However, the purpose of this review is to focus on the use of carbon nanotubes in drug delivery of non-cancerous disease. The novelty of this review is it is focused on the applicability of CNT in the various non-cancerous diseases. Detailed information gathered from the past literature can guide and encourage researchers to explore the applicability of CNT in various non-cancerous diseases in the future.

Carbon Nano Tubes: Novel drug delivery system in amelioration of Alzheimer’s disease

2020 ◽  
Vol 23 ◽  
Author(s):  
Jayanti Mishra ◽  
Bhumika Kumar ◽  
Mukesh Pandey ◽  
Faheem Hyder Pottoo ◽  
Faizana Fayaz ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Carbon Nanotubes ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Drug Delivery System ◽  
Delivery System ◽  
Drug Loading ◽  
Brain Disorder ◽  
Biological Barriers ◽  
The Brain

Background: Alzheimer’s disease is an irreversible, progressive brain disorder manifested with symptoms like loss of memory (known as dementia), personality changes, loss of cognition, impaired movement, confusion, deteriorated planning and thought process. Neurodegeneration in Alzheimer’s disease is the result of deposition of protein beta-amyloid that forms plaques and another protein called tau, forming tangles that prevent proper functioning of nerve cells in the brain. Methods: The goal of the review was to comprehensively study the utilization of nanotechnology and the role that carbon nanotubes can play as a drug delivery system for amelioration of Alzheimer’s disease. Results: Nanotechnology is one of the most researched domains of modern science. It contributes significantly to therapeutics by facilitating drug therapy to reach the target sites, which are otherwise difficult to reach with conventional drug delivery systems. Carbon nanotubes are the allotropes of carbon in which several carbon atoms bind with each other to form a cylindrical or a tube-like structure. The carbon nanotubes possess several unique qualities, which confers them with a high potential of being utilized as an efficient drug delivery system. They offer high drug loading, can readily cross the toughest biological barriers like BBB. Carbon nanotubes also facilitate the passage of drugs to the brain via the olfactory route, which further helps in restoring normal autophagy, thus preventing the elimination of autophagic chemicals. They can carry a vast range of cargos, including drugs, antigens, genetic materials, and biological macromolecules. Conclusion: Carbon nanotubes are highly promising drug delivery system for anti-Alzheimer’s drugs. They have potential of overcoming the various biological barriers like BBB. However, more extensive research is required so as to set up a firm base for development of advanced commercial products based on carbon nanotubes for treatment of Alzheimer’s disease.

scholarly journals The Past and the Future of Alzheimer’s Disease Fluid Biomarkers1

2018 ◽  
Vol 62 (3) ◽  
pp. 1125-1140 ◽  
Author(s):  
Kaj Blennow ◽  
Henrik Zetterberg
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The Past ◽  
The Future

scholarly journals STRENGTH IN AGE: HARNESSING THE BENEFITS OF NIA’S 45 YEARS

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S437-S438
Author(s):  
Marie A Bernard ◽  
Richard Hodes ◽  
Robin A Barr
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Panel Discussion ◽  
National Institutes Of Health ◽  
Special Populations ◽  
Older Individuals ◽  
Aging Research ◽  
The Past ◽  
Age Related ◽  
The Future

Abstract The National Institute on Aging at the National Institutes of Health was established in 1974 with a mission to support and conduct research on aging processes, age-related diseases, and special problems and needs of the aged. Shortly thereafter, the Institute was designated by Congress as the lead research agency in Alzheimer’s disease. During this symposium, NIA’s scientific leadership will reflect on major accomplishments to improve the health of older individuals over the past 45 years and look to the future of the NIA and aging research. This symposium will describe progress led by NIA’s extramural divisions, the intramural program, and the Office of Special Populations. A brief panel discussion will ensue, followed by an informal reception and opportunities for networking in celebration of NIA’s 45 years

Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems

2020 ◽  
Vol 21 (7) ◽  
pp. 628-646
Author(s):  
Gülcem Altinoglu ◽  
Terin Adali
Keyword(s):  
Alzheimer’S Disease ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Neurological Diseases ◽  
Sustained Drug Release ◽  
Physiochemical Properties ◽  
Conventional Drug ◽  
Health Care Burden ◽  
The Central Nervous System ◽  
Effective Drugs

Alzheimer’s disease (AD) is the most common neurodegenerative disease, and is part of a massive and growing health care burden that is destroying the cognitive function of more than 50 million individuals worldwide. Today, therapeutic options are limited to approaches with mild symptomatic benefits. The failure in developing effective drugs is attributed to, but not limited to the highly heterogeneous nature of AD with multiple underlying hypotheses and multifactorial pathology. In addition, targeted drug delivery to the central nervous system (CNS), for the diagnosis and therapy of neurological diseases like AD, is restricted by the challenges posed by blood-brain interfaces surrounding the CNS, limiting the bioavailability of therapeutics. Research done over the last decade has focused on developing new strategies to overcome these limitations and successfully deliver drugs to the CNS. Nanoparticles, that are capable of encapsulating drugs with sustained drug release profiles and adjustable physiochemical properties, can cross the protective barriers surrounding the CNS. Thus, nanotechnology offers new hope for AD treatment as a strong alternative to conventional drug delivery mechanisms. In this review, the potential application of nanoparticle based approaches in Alzheimer’s disease and their implications in therapy is discussed.

Transdermal Drug Delivery Systems and their Potential in Alzheimer’s Disease Management

2020 ◽  
Vol 19 (5) ◽  
pp. 360-373 ◽  
Author(s):  
Panoraia I. Siafaka ◽  
Ece Ö. Bülbül ◽  
Gökce Mutlu ◽  
Mehmet E. Okur ◽  
Ioannis D. Karantas ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Disease Management ◽  
Transdermal Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Oral Dosage ◽  
Transdermal Administration ◽  
Transdermal Drug Delivery Systems

Alzheimer's disease is a neuropathological disease with symptoms such as language problems, confusion as to place or time, loss of interest in activities, which were previously enjoyed, behavioral changes, and memory loss. Alzheimer's disease and other types of dementia affect almost 46.8 million people globally and are estimated to strike about 131.5 million people in 2050. It has been reported that Alzheimer's is the sixth main cause of mortality. The most used drugs, which are currently approved by the Food, and Drug Administration for Alzheimer’s disease are donepezil, rivastigmine, galantamine, memantine, and the combination of donepezil and memantine. However, most of the drugs present various adverse effects. Recently, the transdermal drug delivery route has gained increasing attention as an emerging tool for Alzheimer's disease management. Besides, transdermal drug delivery systems seem to provide hope for the management of various diseases, due to the advantages that they offer in comparison with oral dosage forms. Herein, the current advancements in transdermal studies with potent features to achieve better Alzheimer's disease management are presented. Many researchers have shown that the transdermal systems provide higher efficiency since the first-pass hepatic metabolism effect can be avoided and a prolonged drug release rate can be achieved. In summary, the transdermal administration of Alzheimer's drugs is an interesting and promising topic, which should be further elaborated and studied.

Sign in / Sign up

Export Citation Format

Share Document